Daiichi Sankyo and Eli Lilly (LLY) Confirm FDA Cardio Renal Advisory Committee to Review Prasugrel

December 31, 2008 8:21 AM EST

Daiichi Sankyo Company, Limited and Eli Lilly (NYSE: LLY) confirmed that the U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) will review prasugrel during an advisory committee hearing on February 3, 2009. Prasugrel is an investigational antiplatelet agent for the treatment of patients with acute coronary syndromes (ACS) who are being managed with an artery-opening procedure known as percutaneous coronary intervention (PCI), which is usually followed by the placement of a stent to help keep the artery open.

Advisory committees provide the FDA with independent advice from outside medical experts during the review process. The companies will have further discussions with the FDA in preparation for the Advisory Committee Meeting.

"We have full confidence in the data submitted to the FDA and the overall benefit-risk profile of prasugrel, and we look forward to this next step in potentially bringing an important new alternative to the oral antiplatelet market," said J. Anthony Ware, M.D., Lilly vice president and cardiovascular/acute care platform leader for prasugrel.

Eli Lilly and Company discovers, develops, manufactures and sells products in one business segment, pharmaceutical products. [SM]

Related Categories

FDA

Stocks Mentioned

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?